Warburg-Backed AI Drug Firm Insilico Is Said to Weigh U.S. IPO

Insilico Medicine, a company that uses artificial intelligence to drive drug discovery, is considering a U.S. initial public offering that could raise about $300 million, according to people familiar with the matter.

The Hong Kong-based firm is in talks with investment banks about a possible first-time share sale as soon as later this year, the people said, asking not to be identified because the matter is private.

No final decisions have been made and details such as size, timing and venue could change, the people said. Insilico could also opt to do another private funding round, they said.

Insilico ...